ASRT Assertio Holdings Inc.

Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $14 Million

Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $14 Million

LAKE FOREST, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of common stock at a purchase price of $0.62 per share for gross proceeds of approximately $14.0 million.

Roth Capital Partners acted as the sole placement agent in connection with the offering. After the placement agent fees and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $13.0 million.

The Company intends to use the net proceeds from the offering for general corporate purposes, including general working capital.

The securities described above were being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-252368), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 4, 2021. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website at Copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may be obtained by contacting Roth Capital Partners, LLC, 888 San Clemente, Newport Beach, CA 92660, Attn: Prospectus Department, telephone: 800-678-9147.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Assertio

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital and pain and inflammation. Assertio has grown through business development including licensing, mergers and acquisitions.

Investor Contact

Max Nemmers

Forward Looking Statements

Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” ‘believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio.

Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to the offering. These risks are more fully described in the joint proxy statement/prospectus filed with the SEC in connection with the Merger, Assertio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC, the prospectus supplement relating to the offering and in other filings Assertio makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law. Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.

SOURCE Assertio Holdings, Inc.



EN
09/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Assertio Holdings Inc.

 PRESS RELEASE

Assertio Announces Leadership Transition

Assertio Announces Leadership Transition Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that its Board of Directors (the “Board”) has appointed director Mark L. Reisenauer as the Company’s Chief Executive Officer (“CEO”), effective immediately. As part of this transition,...

 PRESS RELEASE

Assertio Presents First-Ever Real-World Study Showing Patient Experien...

Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data with oral film formulation of clobazamNew data presented during poster session at 150th Annual Meeting of the American Neurological AssociationSYMPAZAN is the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with LG...

 PRESS RELEASE

Assertio to Present New Data from Real-World Evidence Study of SYMPAZA...

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now available on ANA2025 website LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commerci...

 PRESS RELEASE

Assertio to Participate in the HC Wainwright and Lake Street Conferenc...

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at two investor conferences in New York City during September 2025. Company management will host investor meetings at the HC Wainwright Conference on Wednesday, September 10, 2025, taking place at the Lotte New York Palace Hotel. Investors can register and request meetings via their HC Wainwright repr...

 PRESS RELEASE

Assertio Reports Second Quarter 2025 Financial Results

Assertio Reports Second Quarter 2025 Financial Results Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the second quarter ended June 30, 2025. Said Brendan O...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch